VPT Ventripoint Diagnostics Ltd

Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) announces that a
group led by Dr. Kai Laser at the Center for Congenital Heart Defects, Bad
Oeynhausen, Germany, has published the results of a clinical study that
demonstrates the robust application of the VMS heart analysis technology beyond
2D ultrasound imaging in a wide range of cardiac conditions.


"The Ventripoint approach to analyzing the right ventricle of the heart works
for all types of scanning and gives rapid, accurate and important results for
the diagnoses and management of patients with a wide spectrum of complex cardiac
conditions," stated Dr. Laser. 


For the first time, this study shows that the bias often reported between MRI
and echocardiography results are due to analysis technique and not imaging
modality. In the study all three imaging modalities: 2D-echo, 3D echo and
cardiac MRI gave the same results when analyzed using the VMS technique and were
equivalent to the gold-standard MRI analysis using the method of disks.
Historically, the comparison of echocardiography and cardiac MRI analysis has
been discouraged due to unexplained discrepancies. This is an important
consideration when trying to assess a patient's progress over time where
multiple imaging modalities may have been used in the past. Standardization
using the VMS technique for all images would give comparable longitudinal
results and allow for better patient monitoring and treatment decisions. 


The study also showed that the time to complete the analysis on these complex
cases was reduced to 5 minutes using the VMS approach compared to 10 to 30
minutes using conventional techniques. 


A report has been accepted for publication in the Journal of the American
Society of Echocardiography and is entitled "Knowledge-Based Reconstruction of
Right Ventricular Volumes Using Real-time Three-dimensional Echocardiographic as
Well as Cardiac Magnetic Resonance Images: Comparison with a Cardiac Magnetic
Resonance Standard." This study further validates the VMS approach as accurate
and reliable for analyzing MRI images or 3D ultrasound images, when adequate
quality images can be acquired. 


"This study, by an independent group, shows how the VMS technology can be
applied across multiple imaging modalities and provides accurate and equivalent
results for Right Ventricular function," stated Dr. George Adams, CEO of
Ventripoint. "This ability of the VMS greatly increases our market potential, as
it allows us to seek partners who would integrate the VMS approach into MRI and
3D-echocardiography analysis packages, while continuing to market VMS for
routine 2D-echocardiography."


About the Journal of the American Society of Echocardiography 

The Journal of the American Society of Echocardiography, with a monthly print
and digital distribution of over 50,000, is considered the top-tier publication
for peer-reviewed studies related to cardiac ultrasound imaging.


About Ventripoint Diagnostics Ltd. 

Ventripoint has created tools to monitor patients with heart disease, a leading
cause of death in developed countries. VMS(TM) is the first cost-effective and
accurate tool for measuring right ventricle heart function. The Corporation has
a suite of applications for all major heart diseases and imaging modalities
including congenital heart disease, left or right heart failure and normal
hearts - a multi-billion dollar market potential. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release


FORWARD-LOOKING STATEMENTS: The statements made in this news release that are
not historical facts may contain forward-looking information that involves risk
and uncertainties. All statements, other than statements of historical facts,
which address Ventripoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. A
description of assumptions used to develop such forward-looking information and
a description of risk factors that may cause actual results to differ materially
from forward-looking information can be found in Ventripoint's disclosure
documents on the SEDAR website at www.sedar.com. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Ventripoint Diagnostics Ltd.
Dr. George Adams
CEO
(206) 910-9125
gadams@ventripoint.com

Ventripoint Diagnostics (TSXV:VPT)
Historical Stock Chart
From Oct 2024 to Nov 2024

Ventripoint Diagnostics (TSXV:VPT)
Historical Stock Chart
From Nov 2023 to Nov 2024